Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes

European Journal of Pharmacology

Volumn 481, Issue 1, 2003, Pages 25-31

  Weiss, Harvey R ^a   Lazar, Michael J ^a   Punjabi, Kusum ^a   Tse, James ^a   Scholz, Peter M ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

(Rabbit); Cardiac myocyte; Cyclic AMP; Cyclic GMP; Cyclic GMP affected cyclic AMP phosphodiesterases

Indexed keywords

8 BROMO CYCLIC GMP; 9 (2 HYDROXY 3 NONYL)ADENINE; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP; MILRINONE; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INHIBITION; HEART MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0344585459     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.09.006     Document Type: Article

References (27)

1. + channel via protein kinase A and protein kinase G. Circ. Res. 89:2001;1005-1013.
2. Cone J., Wang S., Tandon N., Fong M., Sun B., Sakurai K., Yoshitake M., Kambayashi J., Liu Y. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol. 34:1999;497-504.
3. 2+ channels by cyclic AMP and cyclic GMP-dependent protein kinase in Pleurodeles oocytes. Mol. Cell. Biochem. 168:1997;155-161.
4. Corwell T.L., Arnold E., Boerth N.J. Inhibition of smooth muscle growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am. J. Physiol. 267:1994;C1405-C1413.
5. 2+ current to nitric oxide in frog ventricular myocytes. J. Physiol. (Lond.). 534:2001;109-121.
6. Francis S.H., Turko I.V., Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65:2001;1-52.
7. Gustafsson A.B., Brunton L.L. Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO: role of cGMP-stimulated PDE2. Am. J. Physiol. 283:2002;C463-C471.
8. Hirota Y., Ishida H., Genka C. Physiological concentration of nitric oxide induces positive inotropic effects through cGMP pathway in isolated rat ventricular myocytes. Jpn. J. Physiol. 51:2001;455-461.
9. Hove-Madsen L., Mery P.F., Jurevicius J. Regulation of myocardial calcium channels by cyclic AMP metabolism. Basic Res. Cardiol. 91(Suppl. 2):1996;1-8.
10. Kajimoto K., Hagiwara N., Kasanuki H. Contribution of phosphodiesterase isozymes to the regulation of the L-type calcium current in human cardiac myocytes. Br. J. Pharmacol. 121:1997;1549-1556.
11. Kojda G., Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc. Res. 41:1999;514-523.
12. Levy J.H., Bailey J.M. Phosphodiesterase inhibitors: the inotropes of choice for the new millennium? J. Cardiothorac. Vasc. Anesth. 14:2000;365-366.
13. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J. Biol. Chem. 268:1993;26286-26295.
14. Movsesian M.A. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. J. Am. Coll. Cardiol. 34:1999;318-324.
15. Murad F. The nitric oxide-cGMP signal transduction system for intracellular and intercellular communication. Recent Prog. Horm. Res. 49:1994;239-248.
16. Naim K.L., Rabindranauth P., Weiss H.R., Tse J. Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts. Can. J. Physiol. Pharm. 76:1998;605-712.
17. Shah A.M., MacCarthy P.A. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol. Ther. 86:2000;49-86.
18. 2+ in intact cardiac myocytes. Circ. Res. 74:1994;970-978.
19. Shahid M., Nicholson C.D. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1990;695-698.
20. Steinberg S.F., Brunton L.L. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu. Rev. Pharmacol. Toxicol. 41:2001;751-773.
21. Straznicka M., Gong G., Yan L. Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes. J. Cardiovasc. Pharmacol. 34:1999;229-236.
22. 2+ current in rat ventricular myocytes. Circ. Res. 77:1995;803-812.
23. 2+ channel in human atrial myocytes. J. Physiol. (Lond.). 533:2001;329-340.
24. Wang Y., Wagner M.B., Joyner R.W. cGMP-dependent protein kinase mediates stimulation of L-type calcium current by cGMP in rabbit atrial cells. Cardiovasc. Res. 48:2000;310-322.
25. Weiss H.R., Gong G.X., Straznicka M. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic AMP phosphodiesterases. Can. J. Physiol. Pharm. 77:1999;229-235.
26. Yan L., Lee H., Huang M.W. Opposing functional effects of cyclic GMP and cyclic AMP may act through protein phosphorylation in rabbit cardiac myocytes. J. Auton. Pharm. 20:2000;111-121.
27. 2+-ATPase. Pharmacology. 64:2002;106-112.